title: The effect of pramlintide (amylin analogue) treatment on bone metabolism and bone density in patients with type 1 diabetes mellitus.
abstract: Amylin is a 37-amino-acid peptide related to CGRP and calcitonin. It is co-secreted with insulin from pancreatic beta-cells. Amylin is deficient with type 1 diabetes mellitus. To study the in vivo effects of amylin in humans, diabetic patients are an adequate model of chronic amylin deficiency. We investigated the effect of a 12 months pramlintide therapy (amylin analogue) on bone metabolism in patients with type 1 diabetes mellitus. 23 patients with type 1 diabetes mellitus (age 45.2 +/- 10.3 years, duration of diabetes mellitus 20.7 +/- 9.8 years, 13 male, 10 female) injected themselves 0.1 ml pramlintide, a human amylin analogue, four times per day for a period of 12 months. Bone mineral density measurements of the lumbar spine by dual-energy X-ray absorptiometry (DXA), and biochemical markers of bone metabolism (serum-calcium, PTH, osteocalcin, urinary pyridinium cross-links) were obtained before and one year after starting pramlintide therapy. None of the following parameters changed significantly: bone density, serum calcium, PTH, osteocalcin or pyridinium cross-links. Only osteocalcin decreased from 7.205 ng/ml to 5.825 ng/ml, but this change was not statistically significant. We conclude that a one-year pramlintide therapy does not affect bone density or bone metabolism in patients with type 1 diabetes mellitus without osteopenia (based on the markers used).
authors.affiliation: Medizinische Universitätsklinik Heidelberg, Abteilung für Innere Medizin I, Germany.
authors.forename: A K
authors.initials: AK
authors.lastname: Borm
authors.forename: M S
authors.initials: MS
authors.lastname: Klevesath
authors.forename: V
authors.initials: V
authors.lastname: Borcea
authors.forename: C
authors.initials: C
authors.lastname: Kasperk
authors.forename: M J
authors.initials: MJ
authors.lastname: Seibel
authors.forename: P
authors.initials: P
authors.lastname: Wahl
authors.forename: R
authors.initials: R
authors.lastname: Ziegler
authors.forename: P P
authors.initials: PP
authors.lastname: Naworth
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000682:Amyloid / Q000097:blood / Q000627:therapeutic use*; D015519:Bone Density; D001842:Bone and Bones / Q000187:drug effects / Q000378:metabolism*; D003922:Diabetes Mellitus, Type 1 / Q000188:drug therapy* / Q000378:metabolism*; D005260:Female; D006442:Glycated Hemoglobin / Q000032:analysis; D006801:Humans; D007004:Hypoglycemic Agents / Q000627:therapeutic use*; D058228:Islet Amyloid Polypeptide; D008297:Male; D008875:Middle Aged
chemical_list: D000682:Amyloid; D006442:Glycated Hemoglobin; D007004:Hypoglycemic Agents; D058228:Islet Amyloid Polypeptide; C105254:pramlintide